서지넥스

Market position

A Korean nanoparticle drug-delivery specialist seeking a position in LNP-based gene therapy delivery, including in vivo CAR-T delivery, an area drawing large-scale pharmaceutical investment.

Combines AI-driven design of targeted nanoparticles (the Odysseus platform) with LNP and RNA formulation and manufacturing know-how, and pursues tissue-specific delivery targets such as retina/photoreceptors and in vivo CAR-T.

Technology

Nanoparticle-based delivery, including exosomes, liposomes and lipid nanoparticles, used to deliver chemical drugs, proteins, siRNA and mRNA. The company completed its Odysseus platform, which applies AI to differentiate target from non-target cells and design targeted nanoparticles for high-efficiency binding, applied to solid tumors such as gastric, colorectal and pancreatic cancer. Related work includes microfluidic drug-delivery devices for high-efficiency encapsulation of drugs and genes in nanoparticles, mRNA-loaded nano-formulation production, in vivo delivery of gene editors, and an LNP delivery platform targeting the retina and photoreceptors.

Go-to-market

Partnership- and collaboration-led: research agreements and MOUs with universities (Korea University, Ewha Womans University), research institutes (Korea Research Institute of Chemical Technology) and biotech companies (Rznomics, GenKore, Input/Ipsell), technology-transfer agreements, hospital-based clinical research presence at Seoul St. Mary's Hospital's Omnibus Park, and participation in government and accelerator programs.

Pharmaceutical and biotech developers of gene, RNA and nucleic-acid therapeutics, plus academic and institutional research partners.

Geography

Operations and partnerships centered in South Korea, including tenancy in the Omnibus Park facility at Seoul St. Mary's Hospital; the company website lists a San Francisco, California address.

History

Public records of the company's activity begin in 2021 with technology transfer agreements with Catholic University (AI drug discovery) and the Korea Research Institute of Chemical Technology (a compound to avoid cholecystectomy), a Money Today bio award, and the build-out of the Odysseus AI drug-discovery platform in November 2021. In 2022 the company signed research agreements with Korea University on microfluidic drug delivery and with Ewha Womans University professor Lee Hyukjin on mRNA-loaded nano-formulation production, moved into Omnibus Park at Seoul St. Mary's Hospital, won a national new drug development project for a gallstone dissolving agent, and CEO Kim Se-jun received a commendation from the Minister of Science and Technology. In 2023 it added Ewha professor Lee Hyukjin as vice president and CSO and signed agreements with GenKore on in vivo delivery of gene editors and with Ipsell on mRNA-LNP-based induced pluripotent stem cells. 2024 brought an infectious-disease vaccine patent technology transfer with Ewha Womans University and an KRW 8.5 billion investment round. In 2025 and 2026 the company was selected for Scale-up TIPS, the Super Gap Startup Project, a Ministry of Health and Welfare national project and J&J JLABS.